What can I take to a visit?

The person and the assessment

• I have recorded the treating person’s full name and licence details.
• I have checked the board record for the place where the visit will happen.
• I have described the problem and the change I hope for.
• I have asked what other options we can discuss.

The evidence and the product

• I have asked what research applies to my problem.
• I have asked what is unknown, what harm is possible, and how BPC-157 might affect the medicines I take.
• I have asked for the full ingredient name and who would make it.
• I have asked what a batch test sheet shows and what it cannot show.

The bill and the next step

• I have a written account of fees, tests, follow-up, and any repeating charges.
• I have asked about cancellation and what happens if no treatment is prescribed.
• I know who handles later questions and how to contact that person.
• I have asked whether sport or military rules need a separate check.

Keep the approval question on the page

The Food and Drug Administration (FDA) is the US agency that carries out medicine reviews. FDA records dated September 28, 2026 showed no approved medicine containing BPC-157.

Use that as the starting point for the conversation, even if the offer uses reassuring words.